SCHEMBL20135154

SCHEMBL20135154

Cc1cnc(N2CCN(C(=O)c3ccc(C4(C)NC(=O)NC4=O)c(O)c3)CC2)c(C)c1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.38
CRBN Q96SW2 1/20 0.37
HPGD P15428 2/20 0.37
LMNA P02545 5/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
ADAM17 P78536 1/20 0.36
ADAMTS5 Q9UNA0 1/20 0.36
KDM4E B2RXH2 2/20 0.36
HTT P42858 2/20 0.36
HSP90AA1 P07900 1/20 0.36
HSP90AB1 P08238 1/20 0.36
TP53 P04637 2/20 0.36
MAPT P10636 2/20 0.36
TSHR P16473 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29688775 1.00 ALDH1A1 (0.38) ALDH1A1CRBNHPGDLMNASMN1; SMN2
SCHEMBL20135478 0.90 ADAMTS5 (0.38) ALDH1A1CRBNHPGDLMNASMN1; SMN2
SCHEMBL20134979 0.90 ADAMTS5 (0.38) ALDH1A1CRBNHPGDLMNASMN1; SMN2
SCHEMBL29688445 0.90 ADAMTS5 (0.38) ALDH1A1CRBNHPGDLMNASMN1; SMN2
SCHEMBL29689442 0.90 ADAMTS5 (0.38) ALDH1A1CRBNHPGDLMNASMN1; SMN2
SCHEMBL29688812 0.90 ADAMTS5 (0.38) ALDH1A1CRBNHPGDLMNASMN1; SMN2
SCHEMBL20134976 0.90 ADAMTS5 (0.38) ALDH1A1CRBNHPGDLMNASMN1; SMN2
SCHEMBL29688689 0.88 LMNA (0.46) ALDH1A1LMNASMN1; SMN2KDM4EHTT
SCHEMBL20135604 0.88 LMNA (0.46) ALDH1A1LMNASMN1; SMN2KDM4EHTT
SCHEMBL20135433 0.88 ALDH1A1 (0.36) ALDH1A1CRBNHPGDLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 ALDH1A1 584/4885CRBN 3363/4885HPGD 74/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 ALDH1A1 610/4885CRBN 3419/4885HPGD 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.